AOD-9604: research

AOD-9604 dosage

Typical reported dose: 300–500 mcg once a day, in the morning

• First IV dose range: 25–400 mcg/kg IV over 20 minutes; 3 different active doses per person. single doses, at least 7 days apart, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• IV single dose: 25 mcg/kg: 25 mcg/kg IV once over 20 minutes. one infusion per crossover period, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• IV single dose: 50 mcg/kg: 50 mcg/kg IV once over 20 minutes. one infusion per crossover period, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• IV single dose: 100 mcg/kg: 100 mcg/kg IV once over 20 minutes. one infusion per crossover period, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• Single oral dose: 9 mg: 9 mg orally once as capsules. once in each assigned study period, by mouth. Studied in a trial. Studied in: Adults in the cited study. (source)
• Single oral dose: 27 mg: 27 mg orally once as capsules. once in each assigned study period, by mouth. Studied in a trial. Studied in: Adults in the cited study. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

AOD-9604 side effects and risks

Reported side effects

• Headache reported during oral trials: 24 week trial: 25.9% pooled across active and placebo; the drug specific rate is unknown., mild. Review persistent or severe headaches with a clinician. (source)
• Diarrhea: 24 week trial: 7.8% pooled across active and placebo. One severe event at 54 mg was possibly related., moderate. Seek care for severe or persistent diarrhea or dehydration. (source)
• Gas, nausea and stomach upset: More digestive symptoms at 54 mg daily for 7 days; exact per arm rates were not published., mild (source)
• Injection-site soreness or irritation: IV trials reported isolated local reactions. The rate after consumer subcutaneous use is unknown., mild (source)
• Chest tightness: One severe event at 50 mcg/kg IV in the 23 man study was possibly related., serious. Chest pain or breathing trouble needs urgent assessment. (source)
• Euphoria: Early IV crossover: 5/23 during AOD periods versus 0/23 during placebo; not a subcutaneous rate., mild (source)
• Low-blood-sugar episodes: First IV study: 3 events across all treatments; exposure specific counts were not reported., moderate. Check glucose if symptomatic, especially with diabetes medicines. (source)
• Serious events, including tumors: 12 week study: 4 cancers and 1 lipoma; investigators judged them unrelated. Drug causation is unproven., serious (source)
• Fainting: Later sponsor account reports related serious fainting after placebo and after 0.25 mg oral AOD 9604., serious. Fainting needs prompt medical assessment. (source)
• Fatigue, itching or mood changes: The later sponsor account reports related withdrawals for fatigue, itching and depression; arm rates are unavailable., moderate (source)
• Immune reaction to peptide or impurities: FDA flags immune reaction risk, especially with injections; reliable incidence estimates are unavailable., serious (source)

Stop and get help if

• Swollen tongue or throat, trouble breathing, or collapse: Stop exposure and call emergency services now.
• Chest pain, severe breathlessness, fainting or a sustained racing heart: Seek urgent medical care; call emergency services for severe or ongoing symptoms.
• Spreading injection-site redness, red streaks, swelling or fever: Get prompt medical assessment for a possible infection.
• Severe diarrhea with faintness or inability to keep fluids down: Stop exposure and seek urgent care for possible dehydration.
• Confusion, sweating or shaking with low glucose that does not improve: Use the established diabetes rescue plan and seek urgent help if symptoms persist.

Who should avoid it

• pregnant: Human pregnancy safety is unknown; later trials excluded pregnancy.
• breastfeeding: Milk transfer and infant safety are unknown; later trials excluded breastfeeding.
• tryingToConceive: Human fertility and conception safety are unknown. Later trials required contraception.
• under18: Only adults were studied. No pediatric dose or safety data were found.
• other: A known allergy to the peptide, formulation ingredients or diluent should stop use.
• activeCancer: Active cancer was excluded from later trials. This precaution reflects unknown safety, not proof that AOD-9604 raises IGF-1.
• cancerHistory: Later trials excluded most prior cancers. Long-term cancer risk is unresolved; obtain oncology input.
• kidneyDisease: Dosing in kidney disease is not established. Later trials excluded disorders affecting drug clearance.
• liverDisease: Liver-impairment dosing is unknown. FDA flagged possible liver injury in monkeys; later trials excluded significant liver-test abnormalities.
• diabetes: Early IV studies reported low-blood-sugar events; stable diabetes was allowed in a later oral trial. Injection effects and interactions remain unknown.
• heartCondition: Chest tightness occurred in an IV trial. Safety in significant heart disease is not established.
• uncontrolledBloodPressure: Trials excluded significant illness; uncontrolled blood pressure adds uncertainty to unapproved use.
• seizureDisorder: Later IV trials excluded a seizure history; safety is unknown.
• psychiatricCondition: A later sponsor summary reports a related depression withdrawal. Significant psychiatric illness was excluded from the IV trial.
• surgeryPlanned: Later trials excluded planned surgery. Tell the surgical team about all peptide and supplement use.
• immunosuppressed: Injection products may be contaminated. A lower threshold for assessing fever or a painful, red injection site is prudent.
• testedAthlete: WADA 2026 names AOD-9604 in S2.2.3; it is prohibited in and out of competition.

Interactions

• Insulin and sulfonylureas: No proven AOD interaction. Glucose monitoring deserves review because these drugs lower blood sugar and early IV trials reported low-sugar episodes.
• Anticoagulants and antiplatelet drugs: Needle use can worsen bruising or bleeding. This is an injection precaution, not an established chemical interaction with AOD-9604.
• Growth hormone and GH-releasing peptides: Combination safety is unstudied. GH-raising partners can raise IGF-1 or affect glucose; AOD alone did not raise IGF-1 in the oral trials.
• GLP-1 medicines and retatrutide: Forum stacks have no controlled combination trial. Stomach symptoms and weight changes cannot reliably be assigned to AOD-9604.
• Duplicate growth-hormone fragment products: Aliases and fragment labels can hide duplicate dosing or different peptides. Confirm the sequence and ingredients before comparing products.

Product quality risks

• FDA found inconsistent identity details for free base and acetate, plus missing impurity and endotoxin data.
• Peptide aggregates and synthesis impurities may trigger immune reactions.
• AOD-9604 has been identified in unlabeled seized preparations; a name on a vial does not establish its contents.
• FDA cited sterile-production and ingredient-identity failures in a facility that compounded AOD-9604.

How AOD-9604 works

Animal studies suggest it changes how fat cells store and release fat. It does not act like full growth hormone at the GH receptor. A pain-research target, LanCL1, was identified in rodent and tissue work; its human fat-loss role is unknown.

• Fat-cell pathways involving beta-3 signaling: Animal studies show more fat breakdown and receptor expression; direct receptor activation is unproven.
• GH receptor and IGF-1 pathway: No GH-receptor binding in the cited cell tests and no consistent IGF-1 rise in oral human trials.
• LanCL1: A target identified in 2026 pain experiments; this does not establish a human obesity mechanism.

Half-life: Human half-life is undetermined. The later IV trial could not calculate it from the available samples.